Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Blood Advances
|
December 21, 2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
John Mascarenhas, Francesco Passamonti, Kate Burbury, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Haematologica
|
May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
Srdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
Cancer Research
|
December 30, 2011
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation
Fei Su, William D Bradley, Qiongqing Wang, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 8, 2006
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis
Lee A McDermott, Brian Higgins, Mary Simcox, et al.
British Journal of Cancer
|
February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Petra Martin, Carolyn J Shiau, Maria Pasic, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Nature Medicine
|
October 17, 2017
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma
Wilson X Mai, Laura Gosa, Veerle W Daniels, et al.
Nature Communications
|
January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AML
Anne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Blood Advances
|
December 21, 2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
John Mascarenhas, Francesco Passamonti, Kate Burbury, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Haematologica
|
May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
Srdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
Cancer Research
|
December 30, 2011
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation
Fei Su, William D Bradley, Qiongqing Wang, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 8, 2006
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis
Lee A McDermott, Brian Higgins, Mary Simcox, et al.
British Journal of Cancer
|
February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
Petra Martin, Carolyn J Shiau, Maria Pasic, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
Nature Medicine
|
October 17, 2017
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma
Wilson X Mai, Laura Gosa, Veerle W Daniels, et al.
Nature Communications
|
January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AML
Anne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Page
of 6